Kusum Menon1, Katharine O'Hearn, James Dayre McNally, Anand Acharya, Hector R Wong, Margaret Lawson, Tim Ramsay, Lauralyn McIntyre, Elaine Gilfoyle, Marisa Tucci, David Wensley, Ronald Gottesman, Gavin Morrison, Karen Choong. 1. 1Research Institute, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada. 2Department of Pediatrics, Faculty of Medicine, University of Ottawa, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada. 3Department of Economics, Faculty of Public Affairs, Carleton University, Ottawa, ON, Canada. 4Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH. 5Department of Epidemiology, University of Ottawa and Ottawa Hospital Research Institute (OHRI), University of Ottawa, Ottawa, ON, Canada. 6Clinical Epidemiology Program, School of Epidemiology and Public Health, The Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada. 7Division of Critical Care, Department of Medicine, Ottawa Hospital Research Institute (OHRI), University of Ottawa, Ottawa, ON, Canada. 8Section of Critical Care Medicine, Department of Pediatrics, Alberta Children's Hospital, Calgary, AB, Canada. 9Department of Pediatrics, CHU Sainte-Justine Hospital, Montreal, QC, Canada. 10Department of Pediatrics, Faculty of Medicine, The University of British Columbia, British Columbia Woman and Children's Hospital, Vancouver, BC, Canada. 11Department of Pediatrics, Faculty of Medicine, McGill University, Montreal Children's Hospital, Montreal, QC, Canada. 12Department of Critical Care Medicine, IWK Health Centre, Halifax, NS, Canada. 13Department of Pediatrics, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
Abstract
OBJECTIVES: To describe the use of deferred and prior informed consent models in the context of a low additional risk to standard of care, placebo-controlled randomized controlled trial of corticosteroids in pediatric septic shock. DESIGN: An observational substudy of consent processes in a randomized controlled trial of hydrocortisone versus placebo. SETTING: Seven tertiary level PICUs in Canada. PATIENTS: Children newborn to 17 years inclusive admitted to PICU with suspected septic shock between July 2014 and March 2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Information on the number of families approached, consent rates obtained, and spontaneously volunteered reasons for nonparticipation were collected for both deferred and informed consent. The research ethics board of five of seven centers approved a deferred consent model; however, implementation criteria for use of this model varied across sites. The consent rate using deferred versus prior informed consent was significantly higher (83%; 35/42 vs 58%; 15/26; p = 0.02). The mean times from meeting inclusion criteria to randomization (1.8 ± 1.8 vs 3.6 ± 2.1 hr; p = 0.007) and study drug administration (3.4 ± 2.7 hr vs 4.8 ± 2.1 hr; p = 0.05) were significantly shorter with the use of deferred consent versus prior informed consent. No family member or research ethics board expressed concern following use of deferred consent. CONCLUSIONS: Deferred consent was acceptable in time-sensitive critical care research to most research ethics boards, families, and healthcare providers and resulted in higher consent rates and more efficient recruitment. Larger studies on deferred consent and consistency interpreting jurisdictional guidelines are needed to advance pediatric acute care.
RCT Entities:
OBJECTIVES: To describe the use of deferred and prior informed consent models in the context of a low additional risk to standard of care, placebo-controlled randomized controlled trial of corticosteroids in pediatric septic shock. DESIGN: An observational substudy of consent processes in a randomized controlled trial of hydrocortisone versus placebo. SETTING: Seven tertiary level PICUs in Canada. PATIENTS: Children newborn to 17 years inclusive admitted to PICU with suspected septic shock between July 2014 and March 2016. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Information on the number of families approached, consent rates obtained, and spontaneously volunteered reasons for nonparticipation were collected for both deferred and informed consent. The research ethics board of five of seven centers approved a deferred consent model; however, implementation criteria for use of this model varied across sites. The consent rate using deferred versus prior informed consent was significantly higher (83%; 35/42 vs 58%; 15/26; p = 0.02). The mean times from meeting inclusion criteria to randomization (1.8 ± 1.8 vs 3.6 ± 2.1 hr; p = 0.007) and study drug administration (3.4 ± 2.7 hr vs 4.8 ± 2.1 hr; p = 0.05) were significantly shorter with the use of deferred consent versus prior informed consent. No family member or research ethics board expressed concern following use of deferred consent. CONCLUSIONS: Deferred consent was acceptable in time-sensitive critical care research to most research ethics boards, families, and healthcare providers and resulted in higher consent rates and more efficient recruitment. Larger studies on deferred consent and consistency interpreting jurisdictional guidelines are needed to advance pediatric acute care.
Authors: Katie O'Hearn; Jess Gibson; Karla Krewulak; Rebecca Porteous; Victoria Saigle; Margaret Sampson; Anne Tsampalieros; Nick Barrowman; Saoirse Cameron Journal: Can J Anaesth Date: 2021-12-14 Impact factor: 6.713
Authors: Vicky Chalos; Rob A van de Graaf; Bob Roozenbeek; Adriaan C G M van Es; Heleen M den Hertog; Julie Staals; Lukas van Dijk; Sjoerd F M Jenniskens; Robert J van Oostenbrugge; Wim H van Zwam; Yvo B W E M Roos; Charles B L M Majoie; Hester F Lingsma; Aad van der Lugt; Diederik W J Dippel Journal: Trials Date: 2020-07-14 Impact factor: 2.279
Authors: Kilian M Treurniet; Natalie E LeCouffe; Manon Kappelhof; Yvo B W E M Roos; Charles B L M Majoie; Bart J Emmer; Adriaan C G M van Es; Jelis Boiten; Geert J Lycklama; Koos Keizer; Lonneke S F Yo; Hester F Lingsma; Wim H van Zwam; Inger de Ridder; Robert J van Oostenbrugge; Aad van der Lugt; Diederik W J Dippel; Jonathan M Coutinho Journal: Trials Date: 2021-02-15 Impact factor: 2.279
Authors: Scott L Weiss; Fran Balamuth; Elliot Long; Graham C Thompson; Katie L Hayes; Hannah Katcoff; Marlena Cook; Elena Tsemberis; Christopher P Hickey; Amanda Williams; Sarah Williamson-Urquhart; Meredith L Borland; Stuart R Dalziel; Ben Gelbart; Stephen B Freedman; Franz E Babl; Jing Huang; Nathan Kuppermann Journal: Trials Date: 2021-11-06 Impact factor: 2.728
Authors: F A V Anne Pirson; Wouter H Hinsenveld; Robert-Jan B Goldhoorn; Julie Staals; Inger R de Ridder; Wim H van Zwam; Marianne A A van Walderveen; Geert J Lycklama À Nijeholt; Maarten Uyttenboogaart; Wouter J Schonewille; Aad van der Lugt; Diederik W J Dippel; Yvo B W E M Roos; Charles B L M Majoie; Robert J van Oostenbrugge Journal: Trials Date: 2021-02-24 Impact factor: 2.279